Alzamend Neuro is trading 6.2% up now at $1.19 on October 23, 2026, with no confirmed catalyst identified. - No company-specific announcement explaining the move was found. The latest listed company release was September 16, when it announced regaining Nasdaq listing compliance. - Broader market context is weak rather than supportive and does not clearly explain the gain. - Confidence is low because the cause remains unclear and no confirmed company-specific report is tied to the trading activity.